ATRC vs STVN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ATRC · AtriCure$55.39 ▲ 2.37%
STVN · Stevanato Group$15.65 ▼ 1.76%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ATRC +46.8%
- STVN -33.0%
Head to head
| Metric | ATRC | STVN |
|---|---|---|
| Price | $55.39 | $15.65 |
| Change today | ▲ 2.37% | ▼ 1.76% |
| Market cap | $2.82B | $4.27B |
| Return, 3 months | +12.4% | -29.7% |
| Return, year to date | +40.0% | -21.9% |
| Return, 1 year | +53.1% | -29.8% |
| P/E (TTM) | 178.7 | 28.0 |
| P/B | 5.3 | 2.4 |
| P/E percentile vs own 5y | 94th | 19th |
| Dividend yield | – | 0.39% |
| Revenue growth (YoY, latest qtr) | +15.0% | +7.6% |
| Net profit growth (YoY) | +1,622.1% | +16.0% |
| Gross margin | 76.7% | 29.2% |
| Operating margin | 2.9% | 17.7% |
| Net margin | 2.5% | 11.2% |
| Return on equity | 2.9% | 9.3% |
| Analyst target vs. price | +19.2% | +32.6% |
| Analyst buy share | 75% | 50% |
| RSI (14) | 45 | 43 |
| 30-day volatility | 45.9% | 108.3% |
| Max drawdown, 1 year | -39.0% | -45.3% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- STVN is the largest of the group by market value.
- ATRC has returned the most over the past year.
- STVN carries the lowest trailing P/E.
- ATRC is growing revenue fastest.
- STVN keeps the most profit per dollar of sales.
- ATRC has been the calmest stock over the last 30 days.